Patent Settlement News: Social media discussions intensified after Pfizer announced settlements extending its Vyndamax patent to 2031, aiming to stabilize revenues through 2031. While some viewed this as a positive for long-term stability, shares pulled back sharply amid concerns over growth prospects.
Earnings Anticipation: Traders are eyeing the upcoming May 5 earnings report, with predictions of beats and raised guidance driving optimism. Talk of a potential squeeze to $28.50 or higher persists, fueled by expected strong results and obesity drug data in early June.
Analyst Perspectives: Goldman Sachs held its rating but cut the price target to $26 due to growth worries, while year-to-date gains of 7.6% offer some reassurance. Overall chatter reflects a hold consensus with modest upside potential amid broader sector dynamics.
Note: This discussion summary was generated from an AI condensation of post data.
Pfizer Revenue
Pfizer had revenues of $17.6B in Q4 2025. This is a decrease of -1.16% from the same period in the prior year.
You can track PFE financials on Quiver Quantitative's PFE stock page.
Pfizer Congressional Stock Trading
Members of Congress have traded $PFE stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 2 purchases worth up to $30,000 on 02/10, 11/18 and 2 sales worth up to $30,000 on 03/13, 12/19.
- REPRESENTATIVE J. FRENCH HILL sold up to $250,000 on 12/31.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
Pfizer Hedge Fund Activity
We have seen 1,367 institutional investors add shares of Pfizer stock to their portfolio, and 1,373 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 101,068,901 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $2,516,615,634
- NORGES BANK removed 20,119,761 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $500,982,048
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 17,862,459 shares (-96.2%) from their portfolio in Q4 2025, for an estimated $444,775,229
- PACER ADVISORS, INC. removed 17,574,851 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $437,613,789
- MORGAN STANLEY added 14,342,946 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $357,139,355
- BANK OF NEW YORK MELLON CORP added 13,581,757 shares (+38.9%) to their portfolio in Q4 2025, for an estimated $338,185,749
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 8,837,922 shares (-70.2%) from their portfolio in Q4 2025, for an estimated $220,064,257
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Pfizer Government Contracts
We have seen $513,646 of award payments to $PFE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $410,203
- 4569494415!PROCARDIA XL 30 MG TABLET 100S: $24,723
- 4568572944!NALOXONE 4 MG/10 ML VIAL 10ML: $11,280
- 4568676827!HEXTEND 6%-LACT ELEC BAG 500ML: $11,164
- 4568256080!NALOXONE 4 MG/10 ML VIAL 10ML: $8,460
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Pfizer Analyst Ratings
Wall Street analysts have issued reports on $PFE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/24/2025
To track analyst ratings and price targets for Pfizer, check out Quiver Quantitative's $PFE forecast page.
Pfizer Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 11 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $27.0 on 04/29/2026
- Trung Huynh from RBC Capital set a target price of $25.0 on 04/20/2026
- Jin Zhang from CICC set a target price of $33.0 on 04/16/2026
- Michael Yee from UBS set a target price of $27.0 on 04/13/2026
- Terence Flynn from Morgan Stanley set a target price of $28.0 on 04/10/2026
- Jason Gerberry from B of A Securities set a target price of $26.0 on 04/09/2026
- Vamil Divan from Guggenheim set a target price of $36.0 on 03/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
